blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1198254

EP1198254 - CARRIER-DRUG CONJUGATE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.06.2008
Database last updated on 31.08.2024
Most recent event   Tooltip31.08.2012Lapse of the patent in a contracting state
New state(s): FR		published on 03.10.2012  [2012/40]
Applicant(s)For all designated states
KTB Tumorforschungsgesellschaft mbH
Breisacher Strasse 117
79106 Freiburg / DE
[2002/17]
Inventor(s)01 / KRATZ, Felix
Zum Abtsweingarten 19
79241 Ihringen / DE
 [2002/17]
Representative(s)Müller-Boré & Partner Patentanwälte PartG mbB
Friedenheimer Brücke 21
80639 München / DE
[N/P]
Former [2002/17]Müller-Boré & Partner Patentanwälte
Grafinger Strasse 2
81671 München / DE
Application number, filing date00943777.307.06.2000
[2002/17]
WO2000EP05254
Priority number, dateDE199912647510.06.1999         Original published format: DE 19926475
[2002/17]
Filing languageDE
Procedural languageDE
PublicationType: A2 Application without search report
No.:WO0076550
Date:21.12.2000
Language:DE
[2000/51]
Type: A2 Application without search report 
No.:EP1198254
Date:24.04.2002
Language:DE
The application published by WIPO in one of the EPO official languages on 21.12.2000 takes the place of the publication of the European patent application.
[2002/17]
Type: B1 Patent specification 
No.:EP1198254
Date:15.08.2007
Language:DE
[2007/33]
Search report(s)International search report - published on:EP17.05.2001
ClassificationIPC:A61K47/48
[2002/17]
CPC:
A61K47/643 (EP,US); A61K47/65 (EP,US); A61P29/00 (EP);
A61P31/00 (EP); A61P31/12 (EP); A61P35/00 (EP);
A61P37/00 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2002/17]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:TRÄGER-PHARMAKA-KONJUGATE[2002/17]
English:CARRIER-DRUG CONJUGATE[2002/17]
French:CONJUGUE EXCIPIENT-PRODUIT PHARMACEUTIQUE[2002/17]
Entry into regional phase03.01.2002National basic fee paid 
03.01.2002Designation fee(s) paid 
03.01.2002Examination fee paid 
Examination procedure19.12.2000Request for preliminary examination filed
International Preliminary Examining Authority: EP
03.01.2002Examination requested  [2002/17]
12.03.2002Loss of particular rights, legal effect: Claims
29.04.2002Despatch of communication of loss of particular rights: Claims {1}
16.04.2004Despatch of a communication from the examining division (Time limit: M06)
15.10.2004Reply to a communication from the examining division
29.04.2005Despatch of a communication from the examining division (Time limit: M04)
31.08.2005Reply to a communication from the examining division
05.12.2006Date of oral proceedings
14.12.2006Minutes of oral proceedings despatched
19.02.2007Communication of intention to grant the patent
21.06.2007Fee for grant paid
21.06.2007Fee for publishing/printing paid
Opposition(s)16.05.2008No opposition filed within time limit [2008/30]
Fees paidRenewal fee
26.06.2002Renewal fee patent year 03
25.06.2003Renewal fee patent year 04
29.06.2004Renewal fee patent year 05
28.06.2005Renewal fee patent year 06
28.06.2006Renewal fee patent year 07
26.06.2007Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY15.08.2007
DK15.08.2007
FI15.08.2007
NL15.08.2007
SE15.11.2007
GR16.11.2007
ES26.11.2007
PT15.01.2008
FR11.04.2008
[2012/40]
Former [2009/33]CY15.08.2007
DK15.08.2007
FI15.08.2007
NL15.08.2007
SE15.11.2007
GR16.11.2007
ES26.11.2007
PT15.01.2008
Former [2008/28]DK15.08.2007
FI15.08.2007
NL15.08.2007
SE15.11.2007
GR16.11.2007
ES26.11.2007
PT15.01.2008
Former [2008/26]DK15.08.2007
FI15.08.2007
NL15.08.2007
GR16.11.2007
ES26.11.2007
PT15.01.2008
Former [2008/23]DK15.08.2007
FI15.08.2007
NL15.08.2007
GR16.11.2007
ES26.11.2007
Former [2008/19]FI15.08.2007
NL15.08.2007
GR16.11.2007
ES26.11.2007
Former [2008/10]FI15.08.2007
NL15.08.2007
ES26.11.2007
Former [2008/09]NL15.08.2007
ES26.11.2007
Former [2008/08]ES26.11.2007
Cited inInternational search[DY]DE19636889  (KRATZ FELIX DR [DE]) [DY] 1-18 * page 3, line 18 - line 28; claim - *;
 [E]WO0076551  (KTB TUMORFORSCHUNGS GMBH [DE], et al) [E] 1 * page 17, line 18 - line 26; claim - *;
 [Y]  - KRATZ F ET AL, "PREPARATION, CHARACTERIZATION AND IN VITRO EFFICACY OF ALBUMIN CONJUGATES OF DOXORUBICIN", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN),JP,PHARMACEUTICAL SOCIETY OF JAPAN, (1998), vol. 21, no. 1, ISSN 0918-6158, pages 56 - 61, XP000738275 [Y] 1-18 * figure 1 *
 [XY]  - A. TROUET ET AL., "A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropc drug-carrier conjugate; In vitro and in vivo studies.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, WASHINGTON US, (198201), vol. 79, pages 626 - 629, XP002162367 [X] 1 * figure 1; table 1 * [Y] 1-18

DOI:   http://dx.doi.org/10.1073/pnas.79.2.626
 [DY]  - S. NETZEL-ARNETT, "Comparitive sequence specificities of human 72- and 92-kDa gelatinases (type iv Collagenases) and PUMP (Matrilysin)", BIOCHEMISTRY, EASTON, PA US, (1993), vol. 32, no. 25, pages 6427 - 6432, XP002162368 [DY] 1-18 * table 1 *

DOI:   http://dx.doi.org/10.1021/bi00076a016
 [A]  - M. NICHIFOR ET AL., "Macromolecular prodrugs of 5-fluorouracil. 2: Enzymatic degradation.", JOURNAL OF CONTROLLED RELEASE, AMSTERDAM NL, (1996), vol. 39, pages 79 - 92, XP002162369 [A] 1 * abstract *

DOI:   http://dx.doi.org/10.1016/0168-3659(95)00141-7
 [A]  - G. M. DUBOWCHIK ET AL., "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin.", BIOORG MED CHEM LETT., (199812), vol. 8, no. 23, pages 3341 - 3346, XP002162370 [A] 1-18 * page 3342; table 1 *

DOI:   http://dx.doi.org/10.1016/S0960-894X(98)00609-X
ExaminationWO9308842
    - Derossi et al. (1998) Trends Cell Biol. 8, 84-87.
    - Narazaki et al. (1997) BBA 1338, 275-281.
    - Kratz et al (1999) Crit. Rev. Ther. Drug. Carrier Syst. 16, 245-288.
    - Firestone et al. (1996) J. Controll. Rel. 39, 251-259.
    - Willner et al. (1993) Bioconjugate Chem. 4, 521-527.
    - Derossi et al: (1998) Trends Cell Biol. 8, 84-87.
    - Narazaki et al: (1997) BBA 1338, 275-281.
    - Kratz et al: (1999) Crit. Rev. Ther. Drug. Carrier Syst. 16, 245-288.
    - Firestone et al: (1996) J. Controll. Rel. 39, 251-259.
    - Willner et al: (1993) Bioconjugate Chem. 4, 521-527.
    - Yasuzawa & Tomer (1997) Bioconjugate Chem. 8, 391-399.
    - Burton et al. (1989) Eur. J. Biochem. 179, 379-387.
    - Kratz et al. (2002) J. Med. Chem. 45, 5523-5533 + Supporting info.
    - Kratz et al. (2001) Bioorg. Med. Chem. Lett. 11, 2001-2006.
    - Stehle et al. (1997) Anti-Cancer Drugs 8, 677-685.
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.